Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tegafur. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tegafur SCHEMBL8537231 | 1.00 | LMNA (1.00) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL4552 | 1.00 | LMNA (1.00) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL7698456 | 1.00 | LMNA (1.00) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL4155129 | 0.98 | LMNA (0.97) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL22320166 | 0.98 | LMNA (0.97) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL28304686 | 0.97 | LMNA (0.94) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL28156468 | 0.97 | LMNA (0.94) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL28851751 | 0.96 | LMNA (0.92) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10940658 | 0.95 | LMNA (0.91) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 | |
| Tegafur SCHEMBL1276356 | 0.90 | LMNA (0.81) | LMNAMAPTESR1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 47608 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056884-A | Methods of treating pancreatic cancer | 坎莫森特里克斯公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122028934-A | Combination of CLDN18_2 antibody and chemotherapeutic drug and application thereof | 江苏奥赛康生物医药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122011207-A | CAR-T cell over-expressing H2A.Z as well as preparation method and application thereof | 中国科学院微生物研究所 | 2026-05-12 | — | — | CN | claimed |
| EP-3978473-B1 | COMPOUND CONTAINING AN INDOLEACETIC ACID CORE STRUCTURE AND USE THEREOF | BEIJING AN JIAN XI BIO MEDICAL TECH CO LTD (CN) | 2026-05-06 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4720132-A1 | COMBINATION THERAPIES INVOLVING CLAUDIN 18.2 ANTAGONISTS FOR TREATMENT OF CANCER | Suzhou Transcenta Therapeutics Co., Ltd. (CN) | 2026-04-08 | — | — | EP | claimed |
| US-12595232-B2 | DRG-MDM2-1 for use as a novel Mouse Double Minute 2 (MDM2) inhibitor | BAHCESEHIR UNIVERSITESI (TR) | 2026-04-07 | — | — | US | claimed |
| EP-4714958-A1 | COMBINED THERAPY OF PHOTODYNAMIC THERAPY AND IMMUNE CHECKPOINT INHIBITOR | Shanghai Guangsheng Biopharmaceutical Co., Ltd (CN) | 2026-03-25 | — | — | EP | claimed |
| US-12584131-B2 | Methods of gene therapy | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2026-03-24 | — | — | US | claimed |
| US-20260078184-A1 | LAG-3 COMBINATION THERAPY FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-19 | — | — | US | claimed |
| CN-1088777-A | The preparation method that is used for the chemotherapeutic preparation of directly administering to cancer nidus | CONG FANZI (CN) | 1994-07-06 | — | — | CN | claimed |
| CN-1087263-A | Potentiation fluorouracil and derivant tegafur suppository and preparation method | HEILONGJIANG PROV TUMOUR HOSPI (CN) | 1994-06-01 | — | — | CN | claimed |
| US-5288503-A | WATER-PERMEABLE DIFFUSION BARRIER OF POLYVINYL ALCOHOL | SRCHEM INCORPORATED (US) | 1994-02-22 | — | — | US | claimed |
| US-5260066-A | Cryogel bandage containing therapeutic agent | SRCHEM INCORPORATED (US) | 1993-11-09 | — | — | US | claimed |
| EP-0543015-A1 | COMPOSITION, METHOD AND KIT FOR POTENTIATING ANTITUMOR ACTIVITY AND FOR CURING TUMOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1993-05-26 | — | — | EP | claimed |
| EP-0500953-A1 | ANTINEOPLASTIC EFFECT POTENTIATOR AND ANTINEOPLASTIC AGENT | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1992-09-02 | — | — | EP | claimed |
| EP-0224885-B1 | Antitumor composition. | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1992-05-20 | — | — | EP | claimed |
| EP-0338081-A1 | OILY RECTAL INSTILLATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-10-25 | — | — | EP | claimed |
| US-4863902-A | EPIDERMAL GROWTH FACTOR OR PLATELET DERIVED GROWTH FACTOR | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1989-09-05 | — | — | US | claimed |
| EP-0224885-A1 | Antitumor composition. | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1987-06-10 | — | — | EP | claimed |